Here we report that activation of poly(ADP-ribose) polymerase (PARP) is an important factor in the pathogenesis of endothelial dysfunction in diabetes. Destruction of islet cells with ...

Nearly half of patients with advanced ovarian cancer treated with first-line poly-ADP-ribose polymerase (PARP) inhibitors experienced recurrence in this real-world study, emphasizing the need for ...

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction ...

Figure 1: Domain architecture of the classic poly-ADP-ribose-polymerase PARP1 and the newly characterized mono-ADP-ribosyltransferase PARP10. Figure 2: Classification of the poly-ADP-ribose ...

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction ...

1月9日，新天药业跌1.08%，成交额2694.60万元，换手率1.23%，总市值22.34亿元。 根据AI大模型测算新天药业后市走势。短期趋势看，该股当前无连续增减仓现象，主力趋势不明显。主力没有控盘。中期趋势方面，上方有一定套牢筹码积压。近期筹码减仓，但减仓程度减缓。舆情分析来看，目前市场情绪极度悲观。 1、2020年10月19日公司互动回复：公司在产产品感冒止咳胶囊（批准文号：国药准字Z20 ...

Ovarian cancer has seen a significant shift in its treatment paradigm with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, which are now standard in the maintenance setting ...

Poly (ADP-ribose) polymerase (PARP) inhibitors are used as maintenance therapy after completion of platinum-based chemotherapy in ovarian cancer. However, acquired or de novo resistance to PARP ...

IMPACT Therapeutics has received the China National Medical Products Administration (NMPA) marketing authorisation for ...

Repare Therapeutics (RPTX) announced a re-alignment of resources and a re-prioritization of its clinical portfolio to focus on the continued ...

Upcoming Expected Milestones: RP-3467: Potential best-in-class Polθ ATPase inhibitor Repare is dosing patients in the Phase 1 POLAR clinical trial evaluating RP-3467 alone and in combination with the ...